To assess the utility of targeting MDM2 in MM, we knocked down (KD) MDM2 in two drug-resistant MM cell lines (MM1.R, p53wt; 8226R5, p53null) by siRNA and measured cell viability. The gene discussed is MDM2; the disease is Miyoshi myopathy.